

Technology Advisory Interests Register

Topic: Erdafitinib for treating metastatic or unresectable FGFR-altered urothelial cancer [ID1333]

Publication Date: 12 May 2025

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Elizabeth Thurgar	TAC Committee Member	Direct- financial	In the past 12 months Elizabeth has provided consultancy advice to J&J in an unrelated indication, multiple myeloma.	18/11/2024 11/03/2025	It was agreed that Elizabeth's declaration would not prevent her from participating in discussions on this appraisal
Richard Nicholas	TAC Committee Member	Indirect - Non-Financial Professional Interests	Richard is the clinical lead for the UK MS register. The UK MS Register is working with Merck on a project in an unrelated disease multiple sclerosis.	25/11/2024 11/03/2025	It was agreed that Richard's declaration would not prevent him from participating in discussions on this appraisal
Satish Venkateshan	TAC Committee Member	Direct- financial	Regeneron is developing therapeutics for a broad range of diseases including genitourinary cancers. Satish works for Regeneron, pharmaceuticals/biotech company. He also owns shares in the company and have stock options.	07/02/2025	It was agreed that Satish's declaration would not prevent him from participating in discussions on this appraisal

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Robert Huddart	Clinical Expert	Financial and Indirect Professional Interests	<p>Robert has received either speaking or advisory fees from companies working in this area including Pfizer, Gilead, Astellas, Merck, Roche, Bristol Myers Squibb, Nektar, MSD all less than £3000.</p> <p>Robert's institution has received research funding for research Robert has led from Roche (£1m) and MSD (£165K). The institution has received past royalties from Johnson and Johnson (parent company of Janssen)</p>	15/05/2024	It was agreed that Robert's declaration would not prevent them from providing expert advice to the committee
Amarnath Challapalli	Clinical Expert	Financial and Non-Financial Professional Interests	<p>Amarnath has received speaker Fees from: Advanced Accelerator Applications, Astellas, Bayer, BMS, Eisai Ltd, EUSA, Ipsen, Janssen, Novartis, Pfizer, Sanofi. Advisory boards: Advanced Accelerator Applications, Merck, Regeneron, Sanofi, Janssen</p> <p>Amarnath has also received travel grants for conferences: Astellas, Bayer, EUSA, Ipsen, Janssen, Pfizer, Sanofi</p>	21/11/2024	It was agreed that Amarnath's declaration would not prevent them from providing expert advice to the committee

Name	Role with NICE	Type of interest	Description of interest	Interest declared	Comments
Melanie Costin	Patient Expert	Non-Financial Professional Interests	Melanie works for Fight Bladder Cancer who have received funding from J&J in the past 12 month.	18/09/2024	It was agreed that Melanie's declaration would not prevent them from providing expert advice to the committee